Below are the most recent publications written about "Carcinoma, Squamous Cell" by people in Profiles.
-
Perez-Pacheco CG, Gonzalez-Maldonado LA, Furgal A, Schmitd LB, Constantinescu BSC, Li Y, Gannot N, Perry SK, Rozek L, Wolf G, Emrick JJ, Li P, D'Silva NJ. Nerve Types and Classification of Neurons Innervating Oral Cancer. Clin Cancer Res. 2025 Jul 01; 31(13):2741-2755.
-
Oka T, Smith SS, Oliver-Garcia VS, Lee T, Son HG, Mortaja M, Azin M, Garza-Mayers AC, Huang JT, Nazarian RM, Horn TD, Demehri S. Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. Cell Rep. 2025 May 27; 44(5):115561.
-
Zhu X, Meng X, Mochel MC, Wiliams EA, Dresser K, Tomaszewicz K, Hutchinson L, Bledsoe JR. CYLD-mutated anal squamous cell carcinoma: An uncommon entity associated with cylindroma-like morphology and adverse clinical features. Hum Pathol. 2025 Mar; 157:105765.
-
Zhou P, Yeshoua BJ, Konuthula N, Pan CJ, Ferrandino RM, Holte SE, Rizvi Z, Marchiano EM, Futran ND, Barber BR. Association of Oral Health Determinants With Oral Squamous Cell Carcinoma in Never-Smoking Adults. Head Neck. 2025 Jul; 47(7):2025-2032.
-
Brady JS, Norouzi A, Konuthula N, Lam A, Marchiano E, Futran N, Barber B. Examining the Impact of Race and Sex on the Incidence of Positive Surgical Margins in Oral Cavity Squamous Cell Carcinoma. Head Neck. 2025 May; 47(5):1512-1519.
-
Challapalli A, Stewart G, Shaw H, Davies PJ, Lopez-Baez JC, Ottley EC, Kelly S. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab). Front Immunol. 2024; 15:1408667.
-
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ. Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279. J Clin Oncol. 2024 Jun 01; 42(16):1914-1921.
-
Laus AC, Gomes INF, da Silva ALV, da Silva LS, Milan MB, AparecidaTeixeira S, Martin ACBM, do Nascimento Braga Pereira L, de Carvalho CEB, Crovador CS, de Paula FE, Nascimento FC, de Freitas HT, de Lima Vazquez V, Reis RM, da Silva-Oliveira RJ. Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line. Hum Cell. 2024 Jul; 37(4):1170-1183.
-
Ortiz AE, Ahluwalia J, Anderson RR, Franco W, Brian Jiang SI. Autofluorescence Excitation Imaging of Nonmelanoma Skin Cancer for Margin Assessment Before Mohs Micrographic Surgery: A Pilot Study. Dermatol Surg. 2024 07 01; 50(7):616-619.
-
Cornejo KM, Hutchinson L, O'Donnell P, Meng X, Tomaszewicz K, Shalin SC, Cassarino DS, Chan MP, Quinn TR, Googe PB, Nazarian RM. Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals RAS-Activating Mutations. Arch Pathol Lab Med. 2024 02 01; 148(2):215-222.